NVIVQ — InVivo Therapeutics Holdings Balance Sheet
0.000.00%
Last trade - 00:00
- $1.22m
- -$7.36m
- 13
- 57
- 20
- 20
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 16.7 | 6.6 | 19.5 | 19 | 16.4 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 17.1 | 6.78 | 19.7 | 19.1 | 17.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.1 | 1.28 | 1.01 | 1.36 | 1.07 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 18.4 | 9.32 | 21.9 | 21.8 | 18.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.21 | 2.66 | 1.97 | 2.61 | 2.47 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.27 | 3.74 | 2.72 | 3.65 | 3.08 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 16.1 | 5.58 | 19.2 | 18.1 | 15.7 |
Total Liabilities & Shareholders' Equity | 18.4 | 9.32 | 21.9 | 21.8 | 18.8 |
Total Common Shares Outstanding |